Background: The aim of this study was to examine and test the sensitivity, specificity, and threshold scores of the Montreal Cognitive Assessment (MoCA) and the Mini-Mental State Examination (MMSE) and determine those that best correspond to a clinical diagnosis of dementia with Lewy bodies (DLB).
Methods: Sixty-seven Alzheimer's disease (AD), 36 DLB, and 62 healthy participants without dementia (NC), aged 60 to 90, were enrolled. All three groups took the MoCA and MMSE tests at the same time. The Cochran-Mantel-Haenszel tests and receiver operating characteristics curve analysis were used to compare the different neuropsychological test results among the groups.
Results: The cut-off point of the MoCA for AD was 21/22 with a sensitivity of 95.5% and a specificity of 82.3% (area under the curve (AUC): 0.945), and the cut-off point for DLB was 22/23 with a sensitivity of 91.7% and a specificity of 80.6% (AUC: 0.932). For the MMSE, the cut-off points for AD and for DLB from NC were all 24/25, with a sensitivity of 88.1% and a specificity of 85.5% for AD (AUC: 0.92), and a sensitivity of 77.8% and a specificity of 85.5% for DLB (AUC: 0.895). After controlling sex, age, and education, AD and DLB had lower scores in all MoCA subscales than the NC group (p < 0.05), except for the orientation and naming in DLB. In addition, AD had a lower score in the MoCA orientation (p = 0.03) and short-term memory (p = 0.02) than did DLB.
Conclusions: The MoCA is a more sensitive instrument than the MMSE to screen AD or DLB patients from non-dementia cases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1017/S1041610213001245 | DOI Listing |
Clin Neuropsychol
January 2025
Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Despite significant progress in understanding the factors influencing cognitive function in Parkinson's disease (PD), there is a notable gap in data representation for the Latinx population. This study aims to evaluate the contributors to and disparities in cognitive performance among Latinx patients with PD. A retrospective analysis was conducted based on cross-sectional data encompassing demographic, environmental, motor, and non-motor disease characteristics from the Latin American Research Consortium on the Genetics of PD (LARGE-PD) and the Parkinson's Progression Markers Initiative (PPMI) cohorts.
View Article and Find Full Text PDFBMC Neurol
January 2025
Department of Neurology, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland.
Background: Effects of subthalamic nucleus deep brain stimulation (STN-DBS) on neuropsychiatric symptoms of Parkinson's disease (PD) remain debated. Sensor technology might help to objectively assess behavioural changes after STN-DBS.
Case Presentation: 5 PD patients were assessed 1 before and 5 months after STN-DBS with the Movement Disorders Society Unified Parkinson's Disease Rating Scale part III in the medication ON (plus postoperatively stimulation ON) condition, the Montreal Cognitive Assessment, the Questionnaire for Impulsive-Compulsive Behaviors in Parkinson's Disease Rating Scale present version, the Hospital Anxiety and Depression Scale and the Starkstein Apathy Scale.
Int J Radiat Oncol Biol Phys
February 2025
Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.
Brain Res Bull
January 2025
Department of Acupuncture and Moxibustion, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, China. Electronic address:
Background: Subcortical vascular mild cognitive impairment (svMCI) frequently occurs alongside depressive symptoms, significantly affecting patients' quality of life. While cognitive decline and depressive symptoms are linked to cerebellar changes, the specific relationship between these changes and cognitive status in svMCI patients with depression remains unclear.
Objective: This study aimed to investigates the gray matter volume and functional alterations in the cerebellum of svMCI patients, with and without depressive symptoms, and their correlation with cognitive and depressive symptoms.
Maturitas
January 2025
Escuela Medicina, Universidad Finis Terrae, Santiago de Chile, Chile.
Objective: To determine if the SARC-F tool, used to screen for sarcopenia risk, can also predict mild cognitive impairment (MCI) diagnosed with the Montreal Cognitive Assessment (MoCA) tool.
Methods: This is a sub-analysis of data from a cross-sectional study carried out in postmenopausal women from Latin America (nine countries) in which sociodemographic, clinical, and anthropometric data were collected, and the SARC-F and MoCA tools administered. From the original sample of 1185 women, analysis was performed only among the 772 with natural menopause.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!